

SCIENTIFIC REPORTS



OPEN

PadR-type repressors controlling production of a non-canonical FtsW/RodA homologue and other trans-membrane proteins

Samuel Hauf¹, Lars Möller², Stephan Fuchs³ & Sven Halbedel¹

The Gram-positive bacterium *Listeria monocytogenes* occurs ubiquitously in the environment and infects humans upon ingestion. It encodes four PadR-like repressors, out of which LftR has been characterized previously and was shown to control gene expression in response to the antibiotic aurantimycin produced by other environmental bacteria. To better understand the PadR regulons of *L. monocytogenes*, we performed RNA-sequencing with mutants of the other three repressors LadR, LstR and Lmo0599. We show that LadR is primarily responsible for the regulation of the *mdrL* gene, encoding an efflux pump, while LstR and Lmo0599 mainly regulate their own operons. The *lstR* operon contains the *lmo0421* gene, encoding a homolog of the RodA/FtsW protein family. However, this protein does not possess such functionality, as we demonstrate here. The *lmo0599* operon contains two additional genes coding for the hypothetical trans-membrane proteins *lmo0600* and *lmo0601*. A striking phenotype of the *lmo0599* mutant is its impaired growth at refrigeration temperature. In light of these and other results we suggest that Lmo0599 should be renamed and propose LltR (listerial low temperature regulator) as its new designation. Based on the nature of the PadR target genes we assume that these repressors collectively respond to compounds acting on the cellular envelope.

The Gram-positive bacterium *Listeria monocytogenes* is the causative agent of listeriosis, which is one of the most serious foodborne bacterial infections in humans. The bacterium occurs ubiquitously in the environment and infects humans after consumption of contaminated food. Uncooked and ready-to-eat foods pose the highest risk of infection, the latter because *L. monocytogenes* is able to grow at refrigeration temperatures^{1,2}. Fatality rates of listeriosis are remarkably high compared to other foodborne bacterial pathogens³, and, hence, the control of *L. monocytogenes* in food is of utmost importance for the food-processing industry. *L. monocytogenes* frequently enters the food chain due to its wide-spread presence in the soil, in surface waters, on plants and in the gut of various animals⁴. Aggravating this situation, the bacterium has a profound capacity to resist many conditions used to prevent food spoilage. It is not only able to grow at 4 °C, but it can also grow at high salt concentrations, accepts a wide pH range for growth and tolerates anti-microbial compounds of cold smoke^{5,6}. *L. monocytogenes* readily forms biofilms on glass, plastic and steel surfaces⁷, often complicating effective disinfection of food-processing plants. Moreover, isolates of *L. monocytogenes* frequently are resistant against commonly used disinfectants such as benzalkonium chloride^{8,9} and such benzalkonium-resistant isolates have caused big outbreaks in the past^{10,11}. Thus, an improved understanding of the ecology, survival strategies and stress responses of *L. monocytogenes* is important to reduce the entry and of the bacterium into the food chain and its persistence in food-processing plants.

Among the diverse molecular mechanisms employed by bacteria to sense and respond to environmental stresses are the PadR-type transcriptional regulators. The eponymous protein for this class of repressors is the phenolic acid decarboxylase repressor PadR of the firmicute bacterium *Pediococcus pentosaceus*¹². It activates the expression of phenolic acid decarboxylase (PadA) in response to the exposure to toxic phenolic acids. PadA

¹FG11 Division of Enteropathogenic bacteria and Legionella, Robert Koch Institute, Burgstrasse 37, 38855, Wernigerode, Germany. ²ZBS 4 - Advanced Light and Electron Microscopy, Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany. ³FG13 Nosocomial Pathogens and Antibiotic Resistances, Robert Koch Institute, Burgstrasse 37, 38855, Wernigerode, Germany. Correspondence and requests for materials should be addressed to S.H. (email: halbedels@rki.de)

then converts the toxic phenolic acids into less toxic products, thereby conveying resistance to high levels of phenolic acids^{12,13}. Another well-studied PadR-type repressor, LmrR from *Lactococcus lactis*, activates expression of the *lmrCD* multi drug efflux pump genes upon exposure to small toxic compounds like the antibiotic daunorubicin^{14,15}. Under non-inducing conditions, LmrR represses *lmrCD* transcription by blocking the P_{lmrCD} promoter^{15,16}. Binding of effector molecules induces conformational changes in LmrR causing relieve of repression^{14,17,18} and compound excretion through LmrCD¹⁹.

In *L. monocytogenes*, the PadR-type repressor LftR controls the expression of the *lieAB* genes encoding another antibiotic efflux pump²⁰. Recently, we demonstrated that this efflux pump is expressed when *L. monocytogenes* comes into contact with auranitmycin A²¹, a depsipeptide antibiotic with very potent bactericidal activity against Gram-positive bacteria and produced by soil-dwelling *Streptomyces aurantiacus*²². Thus, LftR and LieAB likely promote survival of *L. monocytogenes* when it comes in contact with *S. aurantiacus* in the soil, its natural reservoir²¹, from where it may eventually enter the food chain.

Next to LftR, three additional PadR-like repressors are encoded in the *L. monocytogenes* EGD-e genome: LadR, LstR and Lmo0599. LadR controls production of the multi drug resistance pump MdrL²³, associated with benzalkonium chloride resistance^{24,25}. LstR was linked to heat resistance²⁶ and Lmo0599 has not been characterized until now. In order to better understand the function of PadR-like regulators in *L. monocytogenes*, we here have identified the regulons of the three mentioned repressors by RNA-Seq and studied the function of their primary effector genes in genetic and functional experiments. In light of the results obtained we suggest to rename Lmo0599 as LltR (listerial low temperature regulator).

Results

Identification of the LadR, LstR and LltR regulons. In order to determine the target genes of LadR, LstR and LltR, the *ladR* and *lstR* genes were removed from the genome by allelic exchange and *lltR* was replaced with a non-functional copy carrying the L49A R51A L52A triple mutation in its helix-turn-helix motif. This triple mutation (*lltR**) was designed to prevent binding of LltR to its recognition site. Next, transcriptomes of the *L. monocytogenes* wild type strain EGD-e and its isogenic Δ *ladR*, Δ *lstR* and *lltR** mutants were analyzed by RNA sequencing. This revealed massive (~150-fold) derepression of the *mdrL* gene in cells lacking LadR (Table 1), which is in good agreement with previous work demonstrating that *mdrL* expression is repressed by LadR²³. MdrL is a multidrug efflux transporter and supposedly transports compounds like ethidium bromide, cefotaxime and other antibiotics out of the cell²⁷. Moderate induction of the *lmo1618-1617* operon²⁸ was also observed in the Δ *ladR* mutant (Table 1), as described previously²⁹. This bicistronic transcription unit comprises the *lmo1618* gene coding for a MarR-type regulator followed by *lmo1617* encoding the multidrug resistance transporter MdrM. MdrM is involved in the secretion of the signal molecule cyclic diadenosine monophosphate (c-di-AMP), which activates the host cytosolic surveillance pathway during intracellular passages^{29,30}. The expression of other genes was not affected, indicating that LadR specifically regulates the expression its three target genes, among which *mdrL* appears to be the primary one.

Deletion of *lstR* caused strong (~140-fold) overexpression of the *lmo0421* and *lmo0423* genes (Table 1), which form a tricistronic operon together with *lstR* (*lmo0423-lstR-lmo0421*)²⁸. While the *lmo0421* gene is one of six *L. monocytogenes* RodA/FtsW paralogs, it is unclear whether it is also involved in peptidoglycan chain polymerization^{31,32}. The *lmo0423* gene shares homology with ECF-type sigma factors (27.9% identity to *Bacillus subtilis* σ^V) and has been designated σ^C ²⁶. All three genes of this operon have been implicated in heat stress response²⁶ and σ^C is also important during cold adaptation³³. Only few possible target genes are known for this sigma factor^{34,35} and its main target is the *lmo0423-lstR-lmo0421* operon itself²⁶. The two divergently transcribed and uncharacterized *lmo0420* and *lmo0419* genes located downstream of the *sigC* operon are also considerably overexpressed in the Δ *lstR* mutant (Table 1). Transcriptional read-through could be an explanation for this. The remaining LstR-affected genes, among which is the *lmo0416* gene coding for a putative transcriptional regulator, show lower fold changes and it remains unclear whether these are direct or secondary effects.

A similar hierarchy in fold changes was observed for genes de-repressed in the *lltR** mutant. Here, the *lltR-lmo0600-lmo0601* operon²⁸ was massively overexpressed (~100- to 150-fold), most likely due to relief of auto-repression through LltR. Derepression of *lmo0602*, located downstream of this operon and transcribed in the same direction could be due to transcriptional read-through. Besides this, six mildly overexpressed genes were found, among those the *liaIH* operon, encoding phage shock proteins³⁶, as well as the *lmo1636* and *lmo1637* genes coding for components of a putative ABC transporter (Table 1).

Promoter fragments controlled by LadR, LstR and Lm0599. To verify the data obtained by RNA-seq, fragments upstream of the *mdrL*, *sigC* and *lltR* genes, all between 200 and 370 bp in length and comprising the start codons of each gene, were fused in frame to the *lacZ* gene. These promoter-*lacZ* fusions were then introduced into wild type and mutant backgrounds lacking their cognate PadR-like repressors. Only background β -galactosidase activities, which did not exceed the values obtained with strain LMSH16 carrying a promoter-less *lacZ* gene for control, were observed for two of the three *lacZ* fusions in wild type cells. An exception was the P_{sigC} promoter that resulted in a roughly fourfold higher β -galactosidase activity in wild type cells when compared to the strain with the promoter-less *lacZ* (Fig. 1a). This increased background activity might be explained by the presence of three promoters in front of the *sigC-lstR-lmo0421* operon, including one σ^C -dependent promoter²⁶. Activity of the P_{sigC}-promoter increased 77-fold in the absence of *lstR*, indicating that induced transcription of the *sigC-lstR-lmo0421* operon in the Δ *lstR* mutant is due to increased promoter activity. Likewise, β -galactosidase activity driven by the P_{mdrL} promoter increased in the absence of *ladR*, even though only 17-fold, and activity of the P_{lltR} promoter increased over 50-fold in the *lltR** mutant (Fig. 1a). Taken together, the activities of the three tested promoters increase substantially in the absence of their cognate PadR repressor proteins. This indicates that LadR, LstR and LltR repress initiation of transcription from the P_{mdrL}, P_{sigC} and P_{lltR} promoters, respectively. We

locus	function	fold induction $\Delta ladR$ /wt	P value
upregulated in $\Delta ladR$			
<i>lmo1409</i>	MdrL major facilitator superfamily efflux pump	153.8 \pm 44.3	0.0003
<i>lmo1618</i>	MarR family transcriptional regulator	4.3 \pm 0.4	0.0003
<i>lmo1617</i>	MdrM multidrug transporter	2.6 \pm 0.8	0.0094
upregulated in $\Delta lstR$		fold induction $\Delta lstR$/wt	
<i>lmo0421</i>	RodA-like rod shape-determining protein	145.0 \pm 11.3	2.6 $\times 10^{-5}$
<i>lmo0423</i>	RNA polymerase factor sigma C	139.3 \pm 19.3	8.6 $\times 10^{-7}$
<i>lmo0420</i>	hypothetical protein, HAD family hydrolase	54.9 \pm 10.2	0.0001
<i>lmo0419</i>	hypothetical protein	7.1 \pm 1.5	0.0035
<i>lmo2773</i>	putative transcription antiterminator	2.4 \pm 0.5	0.0035
<i>lmo2050</i>	excinuclease ABC subunit A	2.3 \pm 0.4	0.0037
downregulated in $\Delta lstR$			
<i>lmo1597</i>	hypothetical protein	0.5 \pm 0.04	0.0083
<i>lmo0416</i>	putative transcriptional regulator	0.5 \pm 0.01	0.0017
<i>lmo0417</i>	hypothetical protein	0.4 \pm 0.02	0.0084
<i>lmo1839</i>	PyrP similar to uracil permease	0.2 \pm 0.06	0.0074
upregulated in <i>lItR</i>*		fold induction <i>lItR</i>*/wt	
<i>lmo0599</i>	LtR, PadR-like transcriptional repressor	150.6 \pm 49.7	4.4 $\times 10^{-5}$
<i>lmo0600</i>	DUF1700 containing hypothetical protein	118.0 \pm 34.3	0.0001
<i>lmo0601</i>	DUF4097 containing hypothetical protein	106.8 \pm 23.8	4.8 $\times 10^{-5}$
<i>lmo0602</i>	hypothetical protein, N-acetyltransferase domain	12.7 \pm 9.1	0.0011
<i>lmo0954</i>	LiaI phage shock protein	3.8 \pm 1.1	0.0024
<i>lmo2487</i>	DUF4097 containing hypothetical protein	3.1 \pm 0.7	0.0072
<i>lmo0955</i>	LiaH phage shock protein	2.6 \pm 0.6	0.0027
<i>lmo1637</i>	putative ABC transporter, permease protein	2.5 \pm 0.2	0.0003
<i>lmo0047</i>	putative lipoprotein	2.4 \pm 0.4	0.0029
<i>lmo1636</i>	putative ABC transporter, ATP binding protein	2.4 \pm 0.4	0.0043

Table 1. *L. monocytogenes* genes deregulated in the $\Delta ladR$, $\Delta lstR$ and *lItR** mutants.

tested induction of all three promoter-*lacZ* fusions in disc diffusion assays on X-Gal containing agar plates with rhodamine 6G, a known inducer of *mdrL* expression in *L. monocytogenes* LO28²³, however, induction was not observed (data not shown). Likewise, none of the three promoter-*lacZ* fusions was induced by ethidium bromide, several antibiotics (penicillin G, fosfomycin, cycloserine, chloramphenicol, tetracycline, spectinomycin, ampicillin, kanamycin, nalidixic acid) or selected disinfectants (benzalkonium, tert-butylhydroquinone, acriflavine).

Effect of PadR repressors on *in vitro* and *in vivo* growth of *L. monocytogenes*. Next, we analyzed the contribution of the three PadR-like repressor proteins to growth in batch culture and inside eukaryotic cells. All three mutant strains grew like wildtype at 37 °C (Fig. 2a), 30 °C or 42 °C (data not shown). In contrast, strain LMSH3 carrying the mutated *lItR** allele was nearly unable to grow at 6 °C, while the other two mutants showed wild type-like growth (Fig. 2b). This growth defect of the *lItR** mutant was also evident during growth on BHI agar plates, but could be complemented by ectopic expression of a native *lItR* allele (Fig. 2c), demonstrating that the *lItR** mutation and no secondary site mutation was the cause of the cold-sensitive phenotype.

The contribution of the three PadR-like repressors to intracellular growth was then studied using the J774 mouse macrophage infection model. This showed that the $\Delta ladR$, $\Delta lstR$ and *lItR** mutant strains were phagocytosed as the wild type strain and that their intracellular growth was unaffected (Fig. S1). Apparently, these proteins are not important during infection under the tested conditions.

Identification of the effector gene of the *lItR* operon. In addition to the LltR repressor itself, the *lItR* operon encodes two more genes²⁸. Immediately downstream of *lItR* is *lmo0600*, encoding a multi-spanning integral membrane protein of unknown function that contains a DUF1700 domain³⁷. Further downstream there is *lmo0601* coding for a hypothetical exoprotein containing a DUF4097 domain³⁷, which is annotated as a possible structural element of bacterial adhesins³⁸. We wondered whether the cold-sensitive growth phenotype of the *lItR** mutant results from overexpression of *lmo0600*, *lmo0601* or both genes. To study this, both genes were individually deleted in the *lItR** mutant background and the ability of the resulting mutants to grow at 6 °C was then tested on BHI agar plates. This revealed that deletion of *lmo0600* restored normal growth in the *lItR** $\Delta lmo0600$ double mutant, whereas the *lItR** $\Delta lmo0601$ was as impaired to grow at 6 °C as the *lItR** single mutant strain (Fig. 3). This shows that overexpression of the transmembrane protein Lmo0600 is detrimental for growth at low temperatures and emphasizes the importance of LltR in repression of *lmo0600* transcription for growth at refrigeration temperature.




Figure 1. Activity of LadR-, LstR- and LltR-dependent promoters. **(a)** β -galactosidase activity in strains carrying *lacZ* fusions of the P_{mdrL} , P_{lltR} and P_{sigC} promoters. Strains LMSH10 (P_{mdrL} - $lacZ$), LMSH11 ($\Delta ladR$ P_{mdrL} - $lacZ$), LMSH14 (P_{lltR} - $lacZ$), LMSH15 ($lltR^*$ P_{lltR} - $lacZ$), LMSH12 (P_{sigC} - $lacZ$) and LMSH13 ($\Delta lstR$ P_{sigC} - $lacZ$) were grown in BHI broth at 37 °C to mid-logarithmic growth phase and β -galactosidase activity was determined. The experiment was repeated three times and average values and standard deviations are shown. Asterisks indicate significant differences ($P < 0.05$). **(b)** Scheme illustrating gene arrangement at the *ladR*, *lstR* and *lltR* loci. Promoters are either adopted from experimental data^{26,28} or predicted using the bprom algorithm⁵⁶. Promoter fragments used for construction of promoter-*lacZ* fusions are indicated.

Analysis of the effector gene of the *sigC* operon. Of particular interest among the PadR-regulated genes is the third gene of the *sigC* operon, *lmo0421*, which represents the effector gene of this operon and encodes an uncharacterized protein with reasonable similarity to FtsW/RodA proteins. Recent evidence showed that these proteins constitute peptidoglycan glycosyltransferases^{31,32}. *L. monocytogenes* encodes six FtsW/RodA proteins in total³⁹, and among these, Lmo0421 represents a non-canonical homologue that clusters separate from RodA and FtsW proteins (Fig. 4a). We wondered whether *lmo0421* could substitute for any of the two FtsW-like or any of the three RodA-like proteins of *L. monocytogenes* when overexpressed. To study this, we first constructed a novel *lstR* mutant (strain LMSH40), in which three critical amino acids in the conserved operator recognition site of LstR were replaced by alanines (*lstR*^{L90A L92A L93A}, designated *lstR**). In this mutant, the overall architecture of the *sigC* operon remains intact, however the P_{sigC} promoter is de-repressed to the same degree as observed in a $\Delta lstR$ deletion mutant (Fig. 4b). Interestingly, expression of the *sigC* operon was completely dependent on σ^C , as inactivation of the *sigC* gene in wild type and in *lstR** backgrounds reduced activity of the P_{sigC} -*lacZ* reporter even below that of strain LMSH12 (wt P_{sigC} -*lacZ*, $P > 0.01$). Apparently, LstR and σ^C jointly control expression of the *sigC* operon in inverse directions. Despite *lmo0421* overexpression in *lstR* inactivated cells, effects on the sensitivity of the *lstR** or *lstR** $\Delta lmo0421$ mutant against antibiotics affecting different steps in cell wall biosynthesis were not detected (Fig. 4c). Alterations in cell wall ultrastructure were also not observed, questioning a possible role of Lmo0421 in cell wall biosynthesis (Fig. S2).

In order to test whether Lmo0421 could substitute for FtsW1 or FtsW2, we then introduced plasmids allowing insertional disruption of *ftsW1* (*lmo1071*) and *ftsW2* (*lmo2688*) into the wild type and the *lstR** mutant. These plasmids are maintained as extrachromosomal replicons at permissive temperature (30 °C) and, consequently, strains transformed with these vectors grow on erythromycin-containing BHI plates at 30 °C (data not shown). However, plasmid replication is blocked and only clones that have integrated the plasmid into the chromosome can grow in the presence of erythromycin at non-permissive temperature (42 °C, Fig. 5a,b). In good agreement with previous results³⁹, *L. monocytogenes* wild type tolerated disruption of *ftsW2* at 42 °C, whereas *ftsW1* could not be inactivated by plasmid integration, illustrating essentiality of *ftsW1* and dispensability of *ftsW2*. Importantly, this gene essentiality pattern was not changed in the *lstR** mutant, clearly demonstrating that overproduced Lmo0421 cannot compensate for the loss of FtsW1 function (Fig. 5c). In order to test whether Lmo0421 can functionally replace one of the three RodA proteins, we first deleted the *rodA2-rodA1* genes in the wild type and the *lstR** mutant. These strains were then transformed with a plasmid that allows insertional disruption of *rodA3*. While *rodA3* can be readily inactivated in wild type and the *lstR** mutant, where the *rodA2-rodA1* genes are still present, this is not possible in the $\Delta rodA2-rodA1$ strain. This result confirms previous findings showing that at least one of the three RodA proteins is required for viability of *L. monocytogenes*³⁹. However, disruption of *rodA3* was also not possible in the *lstR** $\Delta rodA2-rodA1$ mutant, indicating that one of the RodA homologs is required for viability of *L. monocytogenes* even when Lmo0421 is overexpressed. It is important to note that disruption of *ftsW2* is not tolerated in $\Delta rodA2-rodA1$ strains because plasmid insertion into *ftsW2* would separate *rodA3* from




Figure 2. Growth of *L. monocytogenes* *ladR*, *lstR* and *lltR* mutants. **(a)** *L. monocytogenes* strains EGD-e (wt), LMSH1 ($\Delta ladR$), LMSH2 ($\Delta lstR$) and LMSH3 ($lltR^{L49A R51A L52A}$) were grown in BHI broth at 37°C. **(b)** Growth of the same set of strains at 6°C. Growth curves were repeated three times and average values and standard deviations are shown. **(c)** Complementation of the cold-sensitive growth defect of the *lltR* mutant. *L. monocytogenes* strains EGD-e (wt), LMSH3 ($lltR^{L49A R51A L52A}$) and the complemented strain LMSH42 (+*lltR*) were grown for six weeks on BHI agar containing 1 mM IPTG at 6°C.

the promoter of the operon upstream of *lmo2689*²⁸. Taken together, we conclude that Lmo0421 has neither FtsW nor RodA functionality under these conditions.

Discussion

Shared and specific features of the four PadR-type transcriptional repressors of *L. monocytogenes* begin to emerge. The three repressors studied here specifically control transcription of a small set of genes, usually comprising one to two affected transcription units per repressor. Their target genes are strongly repressed under standard growth conditions in wild type and de-repressed roughly 150-fold in the respective repressor mutants. This regulation pattern suggests that they are disadvantageous during exponential growth but highly beneficial under specific conditions. Among the four, LftR is the strongest repressor as it represses its target promoters about 450-fold²¹. Another shared feature is the presence of negative feedback loops in the gene expression control circuits. LftR²¹, LltR and LstR (this work) are autoregulatory by repressing their own genes. Whether LadR represses transcription of its own gene could not be decided based on our RNA-Seq data since the monocistronic *ladR* transcript is simply absent in the $\Delta ladR$ mutant. However, the *ladR* and *mdrL* promoters are in close proximity²³, so that control of both genes by a single LadR operator seems possible. These negative feedback loops switch off transcription when the inducing molecules or conditions are no longer present.




Figure 3. Identification of the effector gene of the *lltR* operon. *L. monocytogenes* strains EGD-e (wt), LMSH3 (*lltR**), LMSH50 (*lltR** Δ *lmo0600*) and LMSH51 (*lltR** Δ *lmo0601*) were grown on BHI agar plates at 6 °C for six weeks.




Figure 4. Susceptibility of *L. monocytogenes* *lltR* and *lmo0421* mutants against antibiotics targeting peptidoglycan biosynthesis. **(a)** UPGMA tree of the six *L. monocytogenes* and the three *B. subtilis* FtsW/RodA homologues. Legend: Substitutions per site. **(b)** Effect of the *lltR*^{L90A L92A L93A} mutation and σ^C inactivation on the activity of the P_{sigC} promoter. *L. monocytogenes* strains LMSH16 (wt, *lacZ*) LMSH12 (wt, P_{sigC} -*lacZ*), LMSH13 (Δ *lltR* P_{sigC} -*lacZ*), LMSH63 (*lltR** P_{sigC} -*lacZ*), LMSH96 (*sigC**; P_{sigC} -*lacZ*) and LMSH97 (*lltR** *sigC** P_{sigC} -*lacZ*) were grown in BHI broth at 37 °C to mid-logarithmic growth phase and β -galactosidase activity was determined. The experiment was repeated three times and average values and standard deviations are shown. Asterisks indicate significant differences (*t*-test, $P < 0.01$). **(c)** *L. monocytogenes* strains EGD-e (wt), LMSH39 carrying the *lltR*^{L90A L92A L93A} mutation (*lltR**) and LMSH40 additionally lacking the *ftsW/rodA* homologue *lmo0421* (*lltR** Δ *lmo0421*) were tested in filter disc susceptibility assays using penicillin G (1 mg/ml), vancomycin (20 mg/ml), moenomycin (1.6 mg/ml), bacitracin (40 mg/ml), fosfomycin (20 mg/ml) or cycloserine (30 mg/ml). Tests were repeated three times and average values and standard deviations are shown.

With σ^C , a second, but positive feedback loop is enmeshed in the control circuit of the *sigC* operon. This creates the possibility to integrate a second signal so that the *sigC* operon would only be fully induced when *LstR* relieves its repression and σ^C is activated. Provided that σ^C is not completely active during exponential




Figure 5. Lmo0421 cannot take over the function of any other FtsW/RodA protein. (a) Scheme showing genetic arrangement of the six *ftsW/rodA* genes in *L. monocytogenes*. (b) Scheme illustrating the way of insertional disruption chosen to inactivate the *ftsW1*, *ftsW2* and *rodA3* genes. (c) Insertional disruption of the *ftsW1*, *ftsW2* and *rodA3* genes in *L. monocytogenes* strains EGD-e (wt), LMSH39 (*lstR**), LMSH67 ($\Delta rodA2-rodA1$) and LMSH68 (*lstR** $\Delta rodA2-rodA1$). Temperature sensitive plasmids designed to disrupt the *ftsW1* (pSAH66), *ftsW2* (pSAH68), or *rodA3* genes (pSAH67) or in Campbell-type integration events were forced to integrate into their respective target gene in the different strain backgrounds during growth on BHI agar plates containing erythromycin at 42 °C. Colony formation indicates chromosomal plasmid integration and target gene disruption as depicted in panel B. Please note that all strains can grow on BHI/erythromycin plates at 30 °C.

growth, this would suggest that we only observe an intermediate level of *sigC-lstR-lmo0421* transcription in the *lstR* mutant. σ^C is important for growth of the *L. monocytogenes* strain 10403 S at low³³ and high temperatures²⁶, but we could not observe similar effects in the *L. monocytogenes* EGD-e background (Fig. 2b and data not shown). *L. monocytogenes* σ^C shares certain homology with extracytoplasmic function (ECF) sigma factors and is the only sigma factor of this type in strain EGD-e²⁶, but it is not known how exactly σ^C contributes to transcription of its operon. Remarkably, the *sigC* operon is not present in the entire *L. monocytogenes* population and only found in strains of phylogenetic lineage II⁴⁰, to which EGD-e and 10403 S belong. Consistent with this observation and in good agreement with previous results^{26,35}, σ^C does only activate its own promoter, so that *lmo0421* is the only target gene of σ^C and *LstR*. ECF sigma factors respond to signals that attack the integrity of the membrane and the cell wall, such as antimicrobial peptides and lytic enzymes⁴¹. RodA/FtsW enzymes act in peptidoglycan biosynthesis as glycosyltransferases mediating elongation of peptidoglycan chains^{31,32,42}. According to our experiments, Lmo0421 cannot take over the function of any of the other five RodA/FtsW enzymes and its overproduction in an *lstR** background did not affect susceptibility against moenomycin that inhibits glycosyltransferase activity in penicillin binding proteins⁴³. This latter observation suggests that Lmo0421 does not contribute to peptidoglycan transglycosylation under these conditions. However, Lmo0421 may functionally replace one of the other FtsW/RodA proteins under more specific conditions, for example when the FtsW/RodA glycosyltransferases are inhibited by more specific drugs. FtsW/RodA inhibitors are not known, but just recently, a supposedly inhibitory molecule of so far unknown structure has been discovered in a natural compound library screen with a *B. subtilis* mutant devoid of all transglycosylase activity mediated by penicillin binding proteins³¹. This compound (preliminary designation 654/A) or related substances might be recognized by *LstR* (and/or σ^C) under conditions where the house-keeping RodA/FtsW enzymes are chemically inactivated, leading to production of Lmo0421 as a 654/-resistant back-up protein. Interestingly, compound 654/A like the inducer of *LftR*, aurantimycin A, is produced by a soil-dwelling *Streptomyces* strain^{21,31}. However, in order to test this hypothesis the identity of 654/A must be elucidated first. Alternatively, Lmo0421 might use chemically modified lipid II as substrate, which may be produced to confer resistance to antimicrobial peptides⁴⁴. Regardless of these considerations, a role for Lmo0421 in cell wall biosynthesis is supported by a spontaneous *lmo0421* mutation found in a stable *L. monocytogenes* L-form strain that lacks a cell wall⁴⁵.

An inducer for *Ltr* is presently not known. Rhodamine 6G was found to induce *mdrL* transcription in the background of *L. monocytogenes* LO28 suggesting that *LadR* senses rhodamine 6G. However, we cannot confirm this for strain EGD-e carrying the P_{mdrL} -*lacZ* fusion in agar diffusion test (data not shown). Moreover, rhodamine dyes are of synthetic compounds and thus, other naturally occurring *LadR* effector molecules must exist. Based on the above mentioned considerations we speculate that these molecules, which need to be identified in future work, might be of streptomycetes origin. This would then be another common feature of listerial *PadR*-like repressors.

Materials and Methods

Bacterial strains and growth conditions. All strains used in this study are listed in Table 2. *L. monocytogenes* was generally cultivated in BHI broth or on BHI agar plates at 37 °C if not stated otherwise. Where required, antibiotics and supplements were added at the following concentrations: erythromycin (5 µg mL⁻¹), kanamycin (50 µg mL⁻¹) and X-Gal (100 µg mL⁻¹). *Escherichia coli* TOP10 was used as standard cloning host⁴⁶.

General methods, manipulation of DNA and oligonucleotide primers. Transformation of *E. coli* and isolation of plasmid DNA was performed according to standard methods⁴⁶. Preparation of electro-competent *L. monocytogenes* cells and transformation of *L. monocytogenes* were done as described elsewhere⁴⁷. Restriction and ligation of DNA was carried out as detailed in the manufacturer's instructions. For restriction free modification of plasmids an altered version of the original QuikChange mutagenesis protocol was employed⁴⁸. All primer sequences are listed in Table 3. Antibiotic susceptibility assays were recorded using filter discs soaked with solutions of antibiotics as indicated. *L. monocytogenes* colonies were grown over night in BHI broth and used to swab-inoculate BHI agar plates. Filter discs soaked with antibiotics were placed on top of the agar surface and the plates were incubated at 37 °C overnight.

Construction of plasmids and strains. Plasmid pSAH1 was constructed for deletion of the *ladR* gene. To this end, fragments up- and downstream of *ladR* were amplified by PCR using the primers SAH32/SAH33 and SAH34/SAH35 and both fragments were fused together by splicing by overlapping extension PCR (SOE-PCR) with SAH32/SAH35 as the primers. The resulting fragment was ligated into pMAD using BamHI/EcoRI.

Plasmid pSAH3 was constructed for removal of *lstR*. To this end, regions up- and downstream of *lstR* were amplified with the primers SAH038/SAH039 and SAH036/SAH037, respectively. These fragments were fused together by SOE-PCR and the resulting fragment was cloned into pMAD using BamHI/NcoI. An unwanted duplication of around 50 bp directly after the BamHI restriction site was removed by digesting the plasmid with BamHI and subsequent self-ligation, finally yielding pSAH3.

Plasmid pSAH5 was constructed for the introduction of the *lltR*^{L49A R51A L52A} triple mutation (*lltR*^{*}) into the chromosome and was obtained in two steps. First, the *lltR* gene was amplified by PCR from EGD-e chromosomal DNA using the primer pair SAH52/SAH53 and cloned into pMAD using EcoRI/NcoI, resulting in plasmid pSAH4. The *L49A R51A L52A* exchanges were then introduced into pSAH4 by quikchange mutagenesis using SAH58/SAH59 as the mutagenic primers.

Plasmid pSAH33 was generated to introduce the *lstR*^{L90A L92A L93A} (*lstR*^{*}) into the chromosome. To this end, fragments upstream and downstream of the region to be mutated were amplified with primers SAH178/SAH177 and SAH176/SAH175 (SAH177 and SAH176 introduced the *lstR*^{*} mutations), both fragments were combined by SOE-PCR and the resulting fragment was introduced into pMAD by restriction-free cloning.

Plasmid pSAH32 facilitates *lmo0421* deletion and was obtained by amplification of fragments up- and downstream of *lmo0421* using the primers SAH178/SAH181 and SAH180/SAH179, respectively. Both fragments were fused together in a SOE-PCR and the resulting fragment was cloned into pMAD using EcoRI/NcoI. Plasmid pSAH32 was then used as the template in a quick change PCR using the primers SAH176/SAH177 to introduced the *lstR*^{*} mutation, yielding pSAH34.

In order to remove *lmo0600* from *lltR*^{*} cells, plasmid pSAH45 was constructed. To this end, fragments up- and downstream of *lmo0600* were amplified in PCRs with SAH212/SAH213 and SAH214/SAH215 and chromosomal DNA of strain LMSH3 (*lltR*^{*}) as the template, respectively, and joined in a SOE-PCR, the product of which was inserted into pMAD by restriction-free cloning.

Plasmid pSAH46 was generated to remove the *lmo0601* gene. Here, *lmo0601* up- and downstream fragments were PCR amplified with SAH216/SAH217 and SAH218/SAH219, respectively, joined by SOE-PCR and inserted into pMAD by restriction-free cloning.

Plasmid pSAH62 was designed for removal of the *rodA2-rodA1* genes. For this, fragments up- and downstream to the *rodA2-rodA1* cluster were amplified with SAH262/SAH261 and SAH260/SAH259, spliced together by SOE-PCR and introduced into pMAD by restriction-free cloning.

Plasmid pSAH69 was constructed by amplification of the 5'- and 3'-halves of *sigC* using the primer pairs SAH256/SAH255 and SAH254/SAH253, respectively, their subsequent joining by SOE-PCR and the cloning of the obtained fragment into pMAD using restriction-free cloning. SAH255 and SAH254 introduced a premature stop codon at the 39th base pair triplet of *sigC* followed by a KpnI site (*sigC*^{*}).

Derivatives of pMAD designed for gene deletions were transformed into the respective *L. monocytogenes* recipient strains and genes were deleted as described elsewhere⁴⁹. All gene deletions were confirmed by PCR.

For insertional disruption of *ftsW1*, *rodA3* and *ftsW2*, plasmids pSAH66, pSAH67 and pSAH68, respectively, were constructed. To this end, internal gene fragments were amplified by PCR using primers SAH257/SAH258 (*ftsW1*), SAH269/SAH270 (*rodA3*) and SAH263/SAH264 (*ftsW2*) and inserted into pMAD by restriction-free cloning. Plasmids pSAH66-67 were then introduced into *L. monocytogenes* strains by electroporation and transformants were selected on BHI agar containing erythromycin at 30 °C.

name	relevant characteristics	source*/reference
plasmids		
pIMK3	$P_{\text{help}}\text{-lacO lacI neo}$	47
pMAD	bla erm bgaB	49
pBP117	lacZ neo	21
pSAH1	$\text{bla erm bgaB } \Delta\text{ladR}$	this work
pSAH3	$\text{bla erm bgaB } \Delta\text{lstR}$	this work
pSAH4	$\text{bla erm bgaB lltR (Imo0599)}$	this work
pSAH5	$\text{bla erm bgaB lltR}^{\text{L49A R51A L52A}}$	this work
pSAH12	$P_{\text{sigC}}\text{-lacZ neo}$	this work
pSAH14	$P_{\text{mdrL}}\text{-lacZ neo}$	this work
pSAH15	$P_{\text{lltR}}\text{-lacZ neo}$	this work
pSAH32	$\text{bla erm bgaB } \Delta\text{lmo0421}$	this work
pSAH33	$\text{bla erm bgaB lstR}^{\text{L90A L92A L93A}}$	this work
pSAH34	$\text{bla erm bgaB lstR}^{\text{L90A L92A L93A}} \Delta\text{lmo0421}$	this work
pSAH37	$P_{\text{help}}\text{-lacO-lltR lacI neo}$	this work
pSAH45	$\text{bla erm bgaB lltR}^{\text{L49A R51A L52A}} \Delta\text{lmo0600}$	this work
pSAH46	$\text{bla erm bgaB lltR}^{\text{L49A R51A L52A}} \Delta\text{lmo0601}$	this work
pSAH62	$\text{bla erm bgaB } \Delta\text{lmo2428-2427}$	this work
pSAH66	$\text{bla erm bgaB 'ftsW1'}$	this work
pSAH67	$\text{bla erm bgaB 'rodA3'}$	this work
pSAH68	$\text{bla erm bgaB 'ftsW2'}$	this work
pSAH69	$\text{bla erm bgaB sigC}^*$	this work
L. monocytogenes strains		
EGD-e	wild type, serovar 1/2a strain	lab collection
LMSH16	attB::lacZ neo	21
LMSH1	$\Delta\text{ladR (Imo1408)}$	pSAH1 \leftrightarrow EGD-e
LMSH2	$\Delta\text{lstR (Imo0422)}$	pSAH3 \leftrightarrow EGD-e
LMSH3	$\text{lltR}^{\text{L49A R51A L52A}}$	pSAH5 \leftrightarrow EGD-e
LMSH10	$\text{attB::P}_{\text{mdrL}}\text{-lacZ neo}$	pSAH14 \rightarrow EGD-e
LMSH11	$\Delta\text{ladR attB::P}_{\text{mdrL}}\text{-lacZ neo}$	pSAH14 \rightarrow LMSH1
LMSH12	$\text{attB::P}_{\text{sigC}}\text{-lacZ neo}$	pSAH12 \rightarrow EGD-e
LMSH13	$\Delta\text{lstR attB::P}_{\text{sigC}}\text{-lacZ neo}$	pSAH12 \rightarrow LMSH2
LMSH14	$\text{attB::P}_{\text{lltR}}\text{-lacZ neo}$	pSAH15 \rightarrow EGD-e
LMSH15	$\text{lltR}^{\text{L49A R51A L52A}} \text{attB::P}_{\text{lltR}}\text{-lacZ neo}$	pSAH15 \rightarrow LMSH3
LMSH39	$\text{lstR}^{\text{L90A L92A L93A}}$	pSAH33 \leftrightarrow EGD-e
LMSH40	$\text{lstR}^{\text{L90A L92A L93A}} \Delta\text{lmo0421}$	pSAH34 \leftrightarrow LMSH39
LMSH42	$\text{lltR}^{\text{L49A R51A L52A}} \text{attB::P}_{\text{help}}\text{-lacO-lltR lacI neo}$	pSAH37 \rightarrow LMSH3
LMSH50	$\text{lltR}^{\text{L49A R51A L52A}} \Delta\text{lmo0600}$	pSAH45 \leftrightarrow LMSH3
LMSH51	$\text{lltR}^{\text{L49A R51A L52A}} \Delta\text{lmo0601}$	pSAH46 \leftrightarrow LMSH3
LMSH63	$\text{lstR}^{\text{L90A L92A L93A}} \text{attB::P}_{\text{sigC}}\text{-lacZ neo}$	pSAH12 \rightarrow LMSH39
LMSH67	$\Delta\text{lmo2428-2427}$	pSAH62 \leftrightarrow EGD-e
LMSH68	$\text{lstR}^{\text{L90A L92A L93A}} \Delta\text{lmo2428-2427}$	pSAH62 \leftrightarrow LMSH39
LMSH89	$\text{sigC}^* \text{ (Imo0423)}$	pSAH69 \leftrightarrow EGD-e
LMSH90	$\text{lstR}^{\text{L90A L92A L93A}} \text{sigC}^*$	pSAH69 \leftrightarrow LMSH39
LMSH96	$\text{sigC}^* \text{ attB::P}_{\text{sigC}}\text{-lacZ neo}$	pSAH12 \rightarrow LMSH89
LMSH97	$\text{lstR}^{\text{L90A L92A L93A}} \text{sigC}^* \text{ attB::P}_{\text{sigC}}\text{-lacZ neo}$	pSAH12 \rightarrow LMSH90

Table 2. Strains and plasmids used in this study. *The arrow (\rightarrow) stands for a transformation event and the double arrow (\leftrightarrow) indicates gene deletions obtained by chromosomal insertion and subsequent excision of pMAD plasmid derivatives (see experimental procedures for details).

For construction of promoter-*lacZ* fusions, fragments carrying the P_{sigC} , P_{mdrL} and P_{lltR} promoters were amplified by PCR using the primer pairs SAH109/SAH110, SAH113/SAH114 and SAH115/SAH116, respectively, and introduced into pBP117 by restriction-free cloning⁵⁰, resulting in plasmids pSAH12, pSAH14 and pSAH15, respectively.

Plasmid pSAH37 for IPTG-dependent expression of *lltR* was generated by amplification of *lltR* using primers SAH185/SAH186 and the insertion of the resulting fragment into pIMK3 by restriction-free cloning.

name	sequence (5' → 3')
SAH32	CAGATCTATCGATGCATGCCATGGAGGAAAGGAAGAGGAGAATTATG
SAH33	AATTCAGAGGTGCTATTGTGTCGACAAAAACCGCGAACTTAATATTCGC
SAH34	ATTAAGTTCGCCGTTTTGTGTCGACACAATAGCACCTCTGAATTC
SAH35	CCTCGCGTCGGGCGATATCGGATCCGGCCGATATTGAACAAATGG
SAH36	CTCGCGTCGGGCGATATCGGATCCAGGGAGATAGCTACTAGGG
SAH37	AGGAGGTTAATCGTCGACATGAGTTCTTCTACATTGAAG
SAH38	TGTAGAAGAACTCATGTGCGACGATTAACCTCCTTTTCATCTTATT
SAH39	CAGATCTATCGATGCATGCCATGGGTTAATCATGGTGGGCGTCCG
SAH52	GATCTATCGATGCATGCCATGGATGGAGGTTAACCCGCAGTTC
SAH53	GCTTCTAGAATTCGAGCTCCCTTATTCATTACTGCTTCCCCCTC
SAH58	CCGGTAGCAAGAGCAGCAGTAAAAGAAGAGTACTGTTTC
SAH59	TTTTACTGCTGCTCTTGCTACCGGATAAATAGCACCTTC
SAH109	CTAGAACTAGTGGATCCCGCATGTTCTTAGCGACTGC
SAH110	GTAAAACGACGGGAATTCCATTAAAGTTTCACCTTCTTCTGC
SAH113	CTAGAACTAGTGGATCCCTATCTTGGGAATGCTTATGAAC
SAH114	GTAAAACGACGGGAATTCCATAATACAACACTACTTCCC
SAH115	CTAGAACTAGTGGATCCCTCACGCATAAACTTATCTCTCC
SAH116	CGACGGGAATTCCTGCAGCATGCTAACTCCTCCATTCTG
SAH175	CTATCGATGCATGCCATGGTCCATCTTCTCCTCCAG
SAH176	GCACATGCAGCTGAAAACAAGAAAATCCTATC
SAH177	AGCTGCATGTGCCAGAATATAAAGCTGACC
SAH178	CTGCAGAAGCTTCTAGAATTCGACAGCGGAAGATTTAACG
SAH179	CTATCGATGCATGCCATGGTGGCAAGGATGAGGAGC
SAH180	CTTATGAGTTAATTTAGTGTATAACCGACATG
SAH181	CACTAAATTAACTCATAAAGAAGCCTCCTC
SAH185	CCCATGGAAAAGGATCCATGGAGGTTAACCCGCAGTTC
SAH186	CGAATTCCTGCAGCCGGGTTATTCATTACTGCTTCCCCCTC
SAH212	CTATCGATGCATGCCATGGATGGAGGTTAACCCGCAGTTC
SAH213	AGTGATGTTTATTCATTACTGCTTCCCCCT
SAH214	TGAATAAACATCACTTAAGCAAAAACT
SAH215	CTGCAGAAGCTTCTAGAATTCATCTTCTCAGGCACCGT
SAH216	CTATCGATGCATGCCATGGTGACCTTGGTAAGCCAGAAG
SAH217	TTCGATTTTATGCATTTTCCCGCCTCC
SAH218	TGCATAAAATCGAAAAATAAAAAATCAGTGCGCT
SAH219	CTGCAGAAGCTTCTAGAATTCAGCTCCGTGCCAAGTCC
SAH253	CTATCGATGCATGCCATGGTCTCTGGCTTGTTTTAAC
SAH254	TTAGGTACCGAATCGAACGACAGCGGAAG
SAH255	TTCGGTACCTAAGAAAAAATAGATGCAGTAC
SAH256	CTGCAGAAGCTTCTAGAATTCGAGAAGAAGGTGAAAC
SAH257	CTATCGATGCATGCCATGGTCTGCTATGTTTATTTGGGC
SAH258	CTGCAGAAGCTTCTAGAATTCATTAAACCATAACCAATCCCA
SAH259	CTATCGATGCATGCCATGGTCTGCTTTCACCCATTC
SAH260	ATGGCCTCTTAAATGAAAATACAGAAGTC
SAH261	CATTTTAAGAGGCCATTGTTTCCGTC
SAH262	CTGCAGAAGCTTCTAGAATTCGATTTAGTGGCGTATGG
SAH263	CTATCGATGCATGCCATGGTTATTACCCACCGCTCCCAATC
SAH264	CTGCAGAAGCTTCTAGAATTCACGAGTTATGGTGTGCTG
SAH269	CTGCAGAAGCTTCTAGAATTCCTGGATTATTTATCGGTGTTTC
SAH270	CTATCGATGCATGCCATGGTTATTATCCCGAACCAACAGC

Table 3. Oligonucleotides used in this study.

Derivatives of pBP117 and pIMK3 were introduced into *L. monocytogenes* strains by electroporation and selected on BHI agar plates containing kanamycin. Plasmid insertion at the *attB* site of the *tRNA^{Arg}* locus was verified by PCR.

mRNA isolation. mRNA was isolated as described previously²¹. Briefly, cells from 25 ml of a culture grown in BHI broth (OD₆₀₀ of ~0.8) was mixed with 25 ml ice cold killing buffer (20 mM Tris-HCl pH 7.5, 5 mM MgCl₂, 20 mM NaN₃) and harvested by centrifugation after 5 min incubation on ice.

RNA extraction followed the protocol of Gertz *et al.*⁵¹ with modifications as described¹⁸. 10 µg total RNA were digested with DNase using the RNase-Free DNase Set (Qiagen) and then purified using RNA clean & concentrator columns (Zymo Research) for purification for RNA molecules longer than 200 nucleotides. RNA quality was assessed using Agilent Bioanalyzer RNA Nano chips. rRNA was depleted using the Ribo-Zero Bacteria Kit (Illumina), 2 µg purified RNA was treated with 10 µl Ribo-ZeroRemoval Solution and pelleted by ethanol precipitation. RNA concentrations were determined in a Qubit® fluorometer.

Library preparation and sequencing. RNA libraries were prepared using the TruSeq® Stranded mRNA Kit as described³⁵. RNA transcripts were quantified by quasi-mapping of the reads to the *L. monocytogenes* EGD-e cDNA (*Listeria_monocytogenes_egd_e.ASM19603v1.cds.all.fa.gz*), provided by the Ensembl Genomes server⁵², using the Salmon software⁵³. Average expression from three biological replicates of the mutant divided by the average expression from three biological replicates of the wildtype gave the differential expression ratio. Log₂-transformed transcript counts from three biological replicates were then used to calculate *P* values using Student's *t*-test. Significantly differentially expressed genes were defined as having a *P*-value less than 0.01, an absolute differential expression factor of more than 2 and an expression level of at least 10 TPM.

β-galactosidase reporter assays. Reporter strain cultures were grown in BHI broth at 37 °C until an OD₆₀₀ of 0.5–0.6. Cells were pelleted, washed once with 500 µl H₂O and then resuspended in 1.2 ml Z-Buffer (60 mM Na₂HPO₄, 40 mM NaH₂PO₄, 10 mM KCl, 1 mM MgSO₄, 20 mM 2-mercaptoethanol). Cells were lysed by sonification and cellular debris was removed by centrifugation. Protein content was determined using Roti®-Nanoquant. Samples were diluted in Z buffer to a final volume of 1 ml and incubated at 30 °C for 10 minutes. The reaction was started by addition of 200 µl ONPG solution (4 mg/ml in Z-Buffer) and stopped by addition of 500 µl 1 M Na₂CO₃ as soon as the first sample turned clearly yellow. Absorption was measured at 420 nm and Miller units (MU) were calculated.

Infection experiments. Experimental infections were carried out as described earlier⁵⁴. Briefly, 3 × 10⁵ J774.A1 mouse ascites macrophages (ATCC) were seeded into the wells of a 24 multi well plate and cultivated in 1 ml high glucose DMEM medium (4.5 g/l glucose, 110 mg/l sodium pyruvate, 584 mg/l L-glutamine) supplemented with 10% fetal calf serum (FCS) for one day at 37 °C in a 5% CO₂ atmosphere. 5 × 10⁴ bacteria from overnight cultures were resuspended in 1 ml of fresh DMEM without FCS and this inoculum was used to infect the J774 cells during an incubation step of 1 h at 37 °C. Next, the wells were washed once with PBS and all extracellular bacteria were killed during another 1 h incubation step in DMEM (without FCS) containing 40 µg/ml gentamicin. The wells were covered with fresh DMEM (without FCS) containing 10 µg/ml gentamicin after one more PBS wash step, and then incubated at 37 °C in a 5% CO₂ atmosphere. Sampling was performed at various time points by lysing the cells in 1 ml of ice-cold PBS containing 0.1% Triton X-100. Serial dilutions were plated on BHI agar plates in order to count the recovered bacterial colonies.

Electron microscopy. Scanning electron microscopy and ultrathin section transmission electron microscopy were performed essentially as described earlier⁵⁵.

Data Availability

RNA sequencing raw files are available at the NCBI Geo Server (<https://www.ncbi.nlm.nih.gov/geo/>) under study accession numbers: GSE129904 (*ladR*), GSE129909 (*lstr*) and GSE129910 (*lhr*).

References

- Walker, S. J., Archer, P. & Banks, J. G. Growth of *Listeria monocytogenes* at refrigeration temperatures. *Journal of Applied Bacteriology* **68**, 157–162, <https://doi.org/10.1111/j.1365-2672.1990.tb02561.x> (1990).
- Schlech, W. F. III Foodborne listeriosis. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* **31**, 770–775, <https://doi.org/10.1086/314008> (2000).
- Charlier, C. *et al.* Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. *Lancet Infect Dis* **17**, 510–519, [https://doi.org/10.1016/S1473-3099\(16\)30521-7](https://doi.org/10.1016/S1473-3099(16)30521-7) (2017).
- Ivanek, R., Grohn, Y. T. & Wiedmann, M. *Listeria monocytogenes* in multiple habitats and host populations: review of available data for mathematical modeling. *Foodborne Pathog Dis* **3**, 319–336, <https://doi.org/10.1089/fpd.2006.3.319> (2006).
- Bucur, F. I., Grigore-Gurgu, L., Crauwels, P., Riedel, C. U. & Nicolau, A. I. Resistance of *Listeria monocytogenes* to stress conditions encountered in food and food processing environments. *Frontiers in microbiology* **9**, 2700, <https://doi.org/10.3389/fmicb.2018.02700> (2018).
- Rorvik, L. M. *Listeria monocytogenes* in the smoked salmon industry. *Int J Food Microbiol* **62**, 183–190 (2000).
- Borucki, M. K., Peppin, J. D., White, D., Loge, F. & Call, D. R. Variation in biofilm formation among strains of *Listeria monocytogenes*. *Applied and Environmental Microbiology* **69**, 7336–7342, <https://doi.org/10.1128/aem.69.12.7336-7342.2003> (2003).
- Mereghetti, L., Quentin, R., Marquet-Van Der Mee, N. & Audurier, A. Low sensitivity of *Listeria monocytogenes* to quaternary ammonium compounds. *Appl Environ Microbiol* **66**, 5083–5086 (2000).
- Aase, B., Sundheim, G., Langsrud, S. & Rorvik, L. M. Occurrence of and a possible mechanism for resistance to a quaternary ammonium compound in *Listeria monocytogenes*. *Int J Food Microbiol* **62**, 57–63 (2000).
- Kovacevic, J. *et al.* Tolerance of *Listeria monocytogenes* to quaternary ammonium sanitizers is mediated by a novel efflux pump encoded by *emrE*. *Appl Environ Microbiol* **82**, 939–953, <https://doi.org/10.1128/AEM.03741-15> (2016).
- Elhanafi, D., Dutta, V. & Kathariou, S. Genetic characterization of plasmid-associated benzalkonium chloride resistance determinants in a *Listeria monocytogenes* strain from the 1998–1999 outbreak. *Appl Environ Microbiol* **76**, 8231–8238, <https://doi.org/10.1128/AEM.02056-10> (2010).
- Barthelmebs, L., Lecomte, B., Divies, C. & Cavin, J. F. Inducible metabolism of phenolic acids in *Pediococcus pentosaceus* is encoded by an autoregulated operon which involves a new class of negative transcriptional regulator. *J Bacteriol* **182**, 6724–6731 (2000).
- Gury, J., Barthelmebs, L., Tran, N. P., Divies, C. & Cavin, J. F. Cloning, deletion, and characterization of *PadR*, the transcriptional repressor of the phenolic acid decarboxylase-encoding *padA* gene of *Lactobacillus plantarum*. *Appl Environ Microbiol* **70**, 2146–2153 (2004).

14. Madoori, P. K., Agustiandari, H., Driessen, A. J. & Thunnissen, A. M. Structure of the transcriptional regulator LmrR and its mechanism of multidrug recognition. *EMBO J* **28**, 156–166, <https://doi.org/10.1038/emboj.2008.263> (2009).
15. Agustiandari, H., Lubelski, J., van den Berg van Saparoea, H. B., Kuipers, O. P. & Driessen, A. J. LmrR is a transcriptional repressor of expression of the multidrug ABC transporter LmrCD in *Lactococcus lactis*. *J Bacteriol* **190**, 759–763, <https://doi.org/10.1128/JB.01151-07> (2008).
16. Agustiandari, H., Peeters, E., de Wit, J. G., Charlier, D. & Driessen, A. J. LmrR-mediated gene regulation of multidrug resistance in *Lactococcus lactis*. *Microbiology* **157**, 1519–1530, <https://doi.org/10.1099/mic.0.048025-0> (2011).
17. Takeuchi, K., Tokunaga, Y., Imai, M., Takahashi, H. & Shimada, I. Dynamic multidrug recognition by multidrug transcriptional repressor LmrR. *Scientific reports* **4**, 6922, <https://doi.org/10.1038/srep06922> (2014).
18. van der Berg, J. P., Madoori, P. K., Komarudin, A. G., Thunnissen, A. M. & Driessen, A. J. Binding of the lactococcal drug dependent transcriptional regulator LmrR to its ligands and responsive promoter regions. *PLoS One* **10**, e0135467, <https://doi.org/10.1371/journal.pone.0135467> (2015).
19. Lubelski, J. *et al.* LmrCD is a major multidrug resistance transporter in *Lactococcus lactis*. *Mol Microbiol* **61**, 771–781, <https://doi.org/10.1111/j.1365-2958.2006.05267.x> (2006).
20. Kaval, K. G., Hahn, B., Tusamda, N., Albrecht, D. & Halbedel, S. The PadR-like transcriptional regulator LftR ensures efficient invasion of *Listeria monocytogenes* into human host cells. *Frontiers in microbiology* **6**, 772, <https://doi.org/10.3389/fmicb.2015.00772> (2015).
21. Hauf, S. *et al.* Aurantimycin resistance genes contribute to survival of *Listeria monocytogenes* during life in the environment. *Mol Microbiol*, *accepted*, <https://doi.org/10.1111/mmi.14205> (2019).
22. Gräfe, U. *et al.* Aurantimycins, new depsipeptide antibiotics from *Streptomyces aurantiacus* IMET 43917. Production, isolation, structure elucidation, and biological activity. *J Antibiot (Tokyo)* **48**, 119–125 (1995).
23. Huillet, E., Velge, P., Vallaes, T. & Pardon, P. LadR, a new PadR-related transcriptional regulator from *Listeria monocytogenes*, negatively regulates the expression of the multidrug efflux pump MdrL. *FEMS Microbiol Lett* **254**, 87–94, <https://doi.org/10.1111/j.1574-6968.2005.00014.x> (2006).
24. Jiang, X. *et al.* MdrL, a major facilitator superfamily efflux pump of *Listeria monocytogenes* involved in tolerance to benzalkonium chloride. *Appl Microbiol Biotechnol*, <https://doi.org/10.1007/s00253-018-9551-y> (2018).
25. Romanova, N. A., Wolffs, P. F., Brovko, L. Y. & Griffiths, M. W. Role of efflux pumps in adaptation and resistance of *Listeria monocytogenes* to benzalkonium chloride. *Appl Environ Microbiol* **72**, 3498–3503, <https://doi.org/10.1128/AEM.72.5.3498-3503.2006> (2006).
26. Zhang, C., Niefertfeldt, J., Zhang, M. & Benson, A. K. Functional consequences of genome evolution in *Listeria monocytogenes*: the lmo0423 and lmo0422 genes encode SigmaC and LstR, a lineage II-specific heat shock system. *J Bacteriol* **187**, 7243–7253, <https://doi.org/10.1128/JB.187.21.7243-7253.2005> (2005).
27. Mata, M. T., Baquero, F. & Perez-Diaz, J. C. A multidrug efflux transporter in *Listeria monocytogenes*. *FEMS Microbiol Lett* **187**, 185–188 (2000).
28. Toledo-Arana, A. *et al.* The *Listeria* transcriptional landscape from saprophytism to virulence. *Nature* **459**, 950–956, <https://doi.org/10.1038/nature08080> (2009).
29. Crimmins, G. T. *et al.* *Listeria monocytogenes* multidrug resistance transporters activate a cytosolic surveillance pathway of innate immunity. *Proc Natl Acad Sci USA* **105**, 10191–10196, <https://doi.org/10.1073/pnas.0804170105> (2008).
30. Woodward, J. J., Iavarone, A. T. & Portnoy, D. A. c-di-AMP secreted by intracellular *Listeria monocytogenes* activates a host type I interferon response. *Science* **328**, 1703–1705, <https://doi.org/10.1126/science.1189801> (2010).
31. Emami, K. *et al.* RodA as the missing glycosyltransferase in *Bacillus subtilis* and antibiotic discovery for the peptidoglycan polymerase pathway. *Nat Microbiol* **2**, 16253, <https://doi.org/10.1038/nmicrobiol.2016.253> (2017).
32. Meeske, A. J. *et al.* SEDS proteins are a widespread family of bacterial cell wall polymerases. *Nature* **537**, 634–638, <https://doi.org/10.1038/nature19331> (2016).
33. Chan, Y. C. *et al.* Contributions of two-component regulatory systems, alternative sigma factors, and negative regulators to *Listeria monocytogenes* cold adaptation and cold growth. *J Food Prot* **71**, 420–425 (2008).
34. Mujahid, S., Orsi, R. H., Boor, K. J. & Wiedmann, M. Protein level identification of the *Listeria monocytogenes* sigma H, sigma L, and sigma C regulons. *BMC Microbiol* **13**, 156, <https://doi.org/10.1186/1471-2180-13-156> (2013).
35. Chaturongakul, S. *et al.* Transcriptomic and phenotypic analyses identify coregulated, overlapping regulons among PrfA, CtsR, HrcA, and the alternative sigma factors sigmaB, sigmaC, sigmaH, and sigmaL in *Listeria monocytogenes*. *Appl Environ Microbiol* **77**, 187–200, <https://doi.org/10.1128/AEM.00952-10> (2011).
36. Jordan, S., Junker, A., Helmann, J. D. & Mascher, T. Regulation of LiaRS-dependent gene expression in *Bacillus subtilis*: Identification of inhibitor proteins, regulator binding sites, and target genes of a conserved cell envelope stress-sensing two-component system. *J Bacteriol* **188**, 5153–5166, <https://doi.org/10.1128/JB.00310-06> (2006).
37. Renier, S., Micheau, P., Talon, R., Hebraud, M. & Desvaux, M. Subcellular localization of extracytoplasmic proteins in monoderm bacteria: rational secretomics-based strategy for genomic and proteomic analyses. *PLoS One* **7**, e42982, <https://doi.org/10.1371/journal.pone.0042982> (2012).
38. Marchler-Bauer, A. *et al.* CDD/SPARCLE: functional classification of proteins via subfamily domain architectures. *Nucleic Acids Res* **45**, D200–D203, <https://doi.org/10.1093/nar/gkw1129> (2017).
39. Risonondo, J., Halbedel, S. & Gründling, A. Cell shape and antibiotic resistance is maintained by the activity of multiple FtsW and RodA enzymes in *Listeria monocytogenes*. *bioRxiv*, 589911, <https://doi.org/10.1101/589911> (2019).
40. Zhang, C. *et al.* Genome diversification in phylogenetic lineages I and II of *Listeria monocytogenes*: identification of segments unique to lineage II populations. *J Bacteriol* **185**, 5573–5584 (2003).
41. Helmann, J. D. *Bacillus subtilis* extracytoplasmic function (ECF) sigma factors and defense of the cell envelope. *Curr Opin Microbiol* **30**, 122–132, <https://doi.org/10.1016/j.mib.2016.02.002> (2016).
42. Taguchi, A. *et al.* FtsW is a peptidoglycan polymerase that is functional only in complex with its cognate penicillin-binding protein. *Nat Microbiol*, <https://doi.org/10.1038/s41564-018-0345-x> (2019).
43. Tamura, T., Suzuki, H., Nishimura, Y., Mizoguchi, J. & Hirota, Y. On the process of cellular division in *Escherichia coli*: isolation and characterization of penicillin-binding proteins 1a, 1b, and 3. *Proc Natl Acad Sci USA* **77**, 4499–4503 (1980).
44. Münch, D. & Sahl, H. G. Structural variations of the cell wall precursor lipid II in Gram-positive bacteria - Impact on binding and efficacy of antimicrobial peptides. *Biochimica et biophysica acta* **1848**, 3062–3071, <https://doi.org/10.1016/j.bbamem.2015.04.014> (2015).
45. Studer, P. *et al.* The Absence of a Mature Cell Wall Sacculus in Stable *Listeria monocytogenes* L-Form Cells Is Independent of Peptidoglycan Synthesis. *PLoS One* **11**, e0154925, <https://doi.org/10.1371/journal.pone.0154925> (2016).
46. Sambrook, J., Fritsch, E. F. & Maniatis, T. *Molecular cloning: a laboratory manual*. 2nd edn, (Cold Spring Harbor Laboratory Press, 1989).
47. Monk, I. R., Gahan, C. G. & Hill, C. Tools for functional postgenomic analysis of *Listeria monocytogenes*. *Appl Environ Microbiol* **74**, 3921–3934, <https://doi.org/10.1128/AEM.00314-08> (2008).
48. Zheng, L., Baumann, U. & Reymond, J. L. An efficient one-step site-directed and site-saturation mutagenesis protocol. *Nucleic Acids Res* **32**, e115 (2004).

49. Arnaud, M., Chastanet, A. & Debarbouille, M. New vector for efficient allelic replacement in naturally nontransformable, low-GC-content, gram-positive bacteria. *Appl Environ Microbiol* **70**, 6887–6891, <https://doi.org/10.1128/AEM.70.11.6887-6891.2004> (2004).
50. van den Ent, F. & Löwe, J. RF cloning: a restriction-free method for inserting target genes into plasmids. *J Biochem Biophys Methods* **67**, 67–74, <https://doi.org/10.1016/j.jbbm.2005.12.008> (2006).
51. Gertz, S. *et al.* Regulation of sigmaB-dependent transcription of sigB and asp23 in two different *Staphylococcus aureus* strains. *Mol Gen Genet* **261**, 558–566 (1999).
52. Kersey, P. J. *et al.* Ensembl Genomes 2018: an integrated omics infrastructure for non-vertebrate species. *Nucleic Acids Res* **46**, D802–D808, <https://doi.org/10.1093/nar/gkx1011> (2018).
53. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. *Nature methods* **14**, 417–419, <https://doi.org/10.1038/nmeth.4197> (2017).
54. Halbedel, S. *et al.* A systematic proteomic analysis of *Listeria monocytogenes* house-keeping protein secretion systems. *Molecular & cellular proteomics: MCP* **13**, 3063–3081, <https://doi.org/10.1074/mcp.M114.041327> (2014).
55. Rismondo, J. *et al.* Discrete and overlapping functions of peptidoglycan synthases in growth, cell division and virulence of *Listeria monocytogenes*. *Mol Microbiol* **95**, 332–351, <https://doi.org/10.1111/mmi.12873> (2015).
56. Solovyev, V. V. Solovyev, A. Salamov (2011) *Automatic Annotation of Microbial Genomes and Metagenomic Sequences*. In *Metagenomics and its Applications in Agriculture, Biomedicine and Environmental Studies* (Ed. Li, R. W.), Nova Science Publishers, p.61–78 (2011).

Acknowledgements

This work was supported by intramural grants of the Robert Koch Institute (to SvH) and a DFG grant (to SvH). We would like to thank Jeanine Rismondo and Angelika Gründling (Imperial College London) for sharing results prior to publication and for helpful discussions. Furthermore, we are grateful to Gudrun Holland and Tobias Hoffmann for excellent technical assistance.

Author Contributions

Sa. H. and L.M. performed the experiments. Sa. H., L.M., S.F. and Sv. H. analysed the data. Sa. H. and Sv. H. wrote the manuscript. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-46347-w>.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019